# Citurgia Biochemicals share price (Citurgia Biochemicals Ltd, NSE: CITURGIA)

> Citurgia Biochemicals share price: ₹102.45 at the NSE close on 19 October 2026, the latest close in our records. > Citurgia Biochemicals Ltd's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. CITURGIA · Chemicals - Organic · data as of 19 October 2026. Page: https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹102.45
- Revenue (Jun 2026): ₹0.0 Cr
- Profit (Jun 2026): −₹0.1 Cr
- ROCE: −2,150%, FY25

Biggest thing to watch: the price has already been rising for 26 weeks, so timing is the risk more than the business. ## What is the Citurgia Biochemicals share price? Citurgia Biochemicals Ltd's share price was ₹102.45 at the close on 19 October 2026. It has been rising for 26 weeks. That is 26.0% above its average price over the last 200 trading days. There is not enough history yet to compare it with the NIFTY 500. Since its first close in our records, on 29 June 2026, it has traded between ₹102 and ₹118, and at that close it was at the low of that range. Over the last 4 months the share price moved −13% while the NIFTY 500 moved −4%, so it is behind the index over that whole period. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What are Citurgia Biochemicals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Citurgia Biochemicals reported revenue of ₹0.00 crore, and a loss of ₹0.08 crore. ### Citurgia Biochemicals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹0.00 crore | ₹0.00 crore | n/a |
| Profit | loss of ₹0.08 crore | loss of ₹0.08 crore | n/a |
| Earnings per share | ₹−0.01 | ₹−0.01 | n/a |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Citurgia Biochemicals share price history? Citurgia Biochemicals closed at ₹102.45 on 19 October 2026. Its highest weekly close since June 2026 was ₹117.55 on 29 June 2026. ### Citurgia Biochemicals share price: then and now

| When | Close | Change to 19 Oct 2026 |
| --- | --- | --- |
| 1 month ago · 21 Sep 2026 | ₹105.50 | −2.9% |
| Earliest and highest weekly close in our records · 29 Jun 2026 | ₹117.55 | −12.8% |
| Lowest weekly close since June 2026 · 19 Oct 2026 | ₹102.45 | 0.0% |

Weekly closing prices. Each change is the move from that price to the 19 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes. (15 weekly closes from 29 June 2026 to 19 October 2026.)

## What is the latest news on Citurgia Biochemicals? 19 Oct 2026: Citurgia Biochemicals closed at ₹102.45, down 2.9% on the month. ## What dividend does Citurgia Biochemicals pay? Citurgia Biochemicals has paid no dividend on the NSE since its first NSE close in our records (29 June 2026), the start of the period we checked. No. Citurgia Biochemicals Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Citurgia Biochemicals on? Citurgia Biochemicals is not on any of our India lists this week. ## Is Citurgia Biochemicals profitable? Citurgia Biochemicals Ltd posted a net loss of ₹0.1 Cr in the Jun 2026 quarter. The full FY26 year was a loss of ₹0.7 Cr. The same quarter a year earlier lost ₹0.1 Cr. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Citurgia Biochemicals make, and is it growing? Citurgia Biochemicals Ltd reported ₹0.0 Cr of revenue in the Jun 2026 quarter. The last full year, FY26, came in at ₹0.0 Cr. The last four reported quarters add to ₹0.0 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly. ## How much of every ₹100 of sales does Citurgia Biochemicals keep? We do not have a clean operating margin for Citurgia Biochemicals Ltd. Its accounts do not report the operating-profit line this section uses, which is common for lenders and holding companies. The other sections show what its filings do report. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Citurgia Biochemicals' profit turning into cash? Citurgia Biochemicals Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹0.1 Cr of cash, against −₹0.7 Cr of profit. After ₹0.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. ## Where does Citurgia Biochemicals' cash go? Citurgia Biochemicals Ltd does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 Cr on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 Cr over the last 3 years, against ₹1.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: almost nothing is being spent on new assets, so the cash goes on running the business. ## What is Citurgia Biochemicals' P/E ratio, and how does it compare with its own history? Citurgia Biochemicals Ltd has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Citurgia Biochemicals business getting better or worse? Citurgia Biochemicals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Citurgia Biochemicals earn on its capital? Citurgia Biochemicals Ltd earned a ROCE of −2,150% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. ## Does Citurgia Biochemicals have too much debt? Citurgia Biochemicals Ltd's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Over 5 years borrowings went from ₹6.5 Cr to ₹6.9 Cr. Over the last 3 of those years it spent ₹0.0 Cr on assets. FY26: borrowings of ₹6.9 Cr against equity of −₹7.7 Cr. Net worth is negative: the company owes more than it owns, so the balance sheet is under water. Part of the spending on assets is being paid for with borrowed money. ## What is the Citurgia Biochemicals shareholding pattern? No group of Citurgia Biochemicals Ltd's owners changed its stake by a full percentage point over the last two years. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −0.3 points over 8 quarters, to 99.4%. ## How far is Citurgia Biochemicals from balance-sheet trouble? For Citurgia Biochemicals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Citurgia Biochemicals rank in its industry? 34.3 out of 100, rank 20 of 20 in Chemicals - Organic, with 25% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Citurgia Biochemicals Ltd scores 34.3 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 20. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 15.7 + 6.1 + 12.5 = 34.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Citurgia Biochemicals compared with? Citurgia Biochemicals ranks 20 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 34.3 out of 100. 1. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) NITTAGELA · quiet · Most evidence points up · 85% evidence 76.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.4/35 · Revenue 15% · Profit 49.4% · Operating margin change 9 points · 100% evidence Capital efficiency 21.3/25 · ROCE 27.7% · Operating margin 28% · 100% evidence Valuation 13.2/20 · P/E 12.1× · PEG 0.95 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 35.5% · 1 year n/a · 25% evidence · 5 of 12 weeks ahead Exact sum: 30.4 + 21.3 + 13.2 + 12 = 76.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) INDOAMIN · losing its lead · Most evidence points up · 81% evidence 66.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 13.3% · Profit 24.2% · Operating margin change 3 points · 88% evidence Capital efficiency 16.8/25 · ROCE 18.9% · Operating margin 14% · 100% evidence Valuation 19.0/20 · P/E 10.6× · PEG 0.32 · 100% evidence Relative strength 9.5/20 · Lead over its industry n/a · Lead over NIFTY 500 2.3% · 1 year -10.4% · 25% evidence · 4 of 12 weeks ahead Exact sum: 20.8 + 16.8 + 19 + 9.5 = 66.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) VALIANTORG · breaking out · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 1.5% · Profit 100% · Operating margin change 6 points · 83% evidence Capital efficiency 9.0/25 · ROCE 5.5% · Operating margin 18% · 76% evidence Valuation 10.9/20 · P/E 23.2× · PEG n/a · 50% evidence Relative strength 19.8/20 · Lead over its industry 24.1% · Lead over NIFTY 500 48.6% · 1 year 39.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 9 + 10.9 + 19.8 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) OCCLLTD · breaking out · Too little evidence to rank firmly · 56% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 40.6% · Profit 100% · Operating margin change 7 points · 83% evidence Capital efficiency 12.3/25 · ROCE 13% · Operating margin 28% · 76% evidence Valuation 11.1/20 · P/E 11× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 45.3% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.6 + 12.3 + 11.1 + 12.1 = 59.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) BASF · quiet · Evidence leans up · 71% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 6.5% · Profit 62.4% · Operating margin change 4 points · 88% evidence Capital efficiency 11.7/25 · ROCE 14.5% · Operating margin 10% · 100% evidence Valuation 14.1/20 · P/E 21.4× · PEG n/a · 50% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -13% · 1 year -30.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 23.8 + 11.7 + 14.1 + 7.7 = 57.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Elantas Beck India Ltd](https://www.sectoralpha.in/stocks/elantas-beck-india-ltd) ELANTAS · leader · Evidence leans up · 67% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 18.7% · Profit 35.5% · Operating margin change 1 points · 95% evidence Capital efficiency 18.1/25 · ROCE 21.2% · Operating margin 23% · 76% evidence Valuation 6.5/20 · P/E 54.1× · PEG n/a · 50% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 31.9% · 1 year 33.1% · 25% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 18.1 + 6.5 + 11.8 = 57.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 7. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) FINEORG · leader · Evidence leans up · 96% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 7.1% · Profit 5.8% · Operating margin change 4 points · 88% evidence Capital efficiency 17.8/25 · ROCE 21.5% · Operating margin 25% · 100% evidence Valuation 15.0/20 · P/E 35.3× · PEG 0.58 · 100% evidence Relative strength 9.9/20 · Lead over its industry -7.6% · Lead over NIFTY 500 12.4% · 1 year 13.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 13.9 + 17.8 + 15 + 9.9 = 56.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 8. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) LXCHEM · quiet · Evidence leans up · 81% evidence 54.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 5.5% · Profit 26% · Operating margin change 7.6 points · 88% evidence Capital efficiency 10.8/25 · ROCE 4.7% · Operating margin 12% · 100% evidence Valuation 13.1/20 · P/E 33.8× · PEG 1.14 · 100% evidence Relative strength 9.2/20 · Lead over its industry n/a · Lead over NIFTY 500 1.8% · 1 year -22% · 25% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 10.8 + 13.1 + 9.2 = 54.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) BALAMINES · quiet · Evidence leans up · 78% evidence 53.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 11.1% · Profit 41.6% · Operating margin change 10 points · 83% evidence Capital efficiency 13.1/25 · ROCE 11% · Operating margin 25% · 76% evidence Valuation 9.1/20 · P/E 28× · PEG n/a · 50% evidence Relative strength 8.2/20 · Lead over its industry -2.5% · Lead over NIFTY 500 15.2% · 1 year 25.3% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.2 + 13.1 + 9.1 + 8.2 = 53.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) FAIRCHEMOR · quiet · Evidence leans up · 100% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 17.1% · Profit 100% · Operating margin change 6.2 points · 100% evidence Capital efficiency 7.0/25 · ROCE 3.3% · Operating margin 10% · 100% evidence Valuation 13.0/20 · P/E 32.7× · PEG 0.84 · 100% evidence Relative strength 3.0/20 · Lead over its industry -15.4% · Lead over NIFTY 500 3.2% · 1 year -15.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 30.3 + 7 + 13 + 3 = 53.3 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -15.9%. 11. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) SIGACHI · breaking out · Evidence leans down · 100% evidence 49.4 out of 100 Growth Capital Valuation Relative
12. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) GFLLIMITED · breaking out · Evidence leans down · 71% evidence 48.6 out of 100 Growth Capital Valuation Relative
13. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) JYOTIRES · basing · Evidence leans down · 74% evidence 43.7 out of 100 Growth Capital Valuation Relative
14. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) FOSECOIND · leader · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
15. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) SGRL · breaking out · Evidence leans down · 85% evidence 40.3 out of 100 Growth Capital Valuation Relative
16. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) OAL · leader · Evidence leans down · 74% evidence 36.5 out of 100 Growth Capital Valuation Relative
17. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) GEMAROMA · quiet · Too little evidence to rank firmly · 51% evidence 32.2 out of 100 Growth Capital Valuation Relative
18. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) SACHEEROME · losing its lead · Too little evidence to rank firmly · 36% evidence 58.1 out of 100 Growth Capital Valuation Relative
19. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) SHRIAHIMSA · leader · Too little evidence to rank firmly · 47% evidence 56.8 out of 100 Growth Capital Valuation Relative
20. Citurgia Biochemicals Ltd this page CITURGIA · Too little evidence to rank firmly · 25% evidence 34.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.7/43.75 · Revenue n/a · Profit -68.2% · Operating margin change n/a · 29% evidence Capital efficiency 6.1/31.25 · ROCE -2150% · Operating margin n/a · 61% evidence Valuation 12.5/25 · P/E n/a · PEG n/a · 0% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 15.7 + 6.1 + 12.5 = 34.3 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Organic](https://www.sectoralpha.in/sectors/chemicals-organic), all 20 compared on one page. ## Which companies are close to Citurgia Biochemicals in size? Citurgia Biochemicals is the 9th largest of 20 Chemicals - Organic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Laxmi Organic Industries, Oriental Aromatics and Nitta Gelatin India. Just below it: Sigachi Industries, Jyoti Resins and Adhesives and Shri Ahimsa Naturals. ### Chemicals - Organic companies close in size

1. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) ₹4,245 crore
2. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) ₹1,916 crore
3. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) ₹1,489 crore
4. Citurgia Biochemicals Ltd ₹1,449 crore
5. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) ₹1,007 crore
6. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) ₹1,006 crore
7. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) ₹952 crore

[All 20 Chemicals - Organic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-organic#all-companies)

### Companies close in size in other industries

1. [Aurum Proptech Ltd](https://www.sectoralpha.in/stocks/aurum-proptech-ltd) ₹1,451 crore · IT Enabled Services
2. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) ₹1,450 crore · Speciality Chemicals
3. Citurgia Biochemicals Ltd ₹1,449 crore
4. [BF Investment Ltd](https://www.sectoralpha.in/stocks/bf-investment-ltd) ₹1,448 crore · Finance & Investments - Others
5. [Divine Power Energy Ltd](https://www.sectoralpha.in/stocks/divine-power-energy-ltd) ₹1,444 crore · Metals

## What else do people ask about Citurgia Biochemicals? ### What is Citurgia Biochemicals's share price? Citurgia Biochemicals Ltd's share price is ₹102.45. The whole company is worth ₹1,449 Cr on the market. It is at its lowest price of the past 52 weeks (range ₹102 to ₹118), 26.0% above its 200-day average. The price has been rising for 26 weeks (as of 19 October 2026). ### What were Citurgia Biochemicals's latest quarterly results? Citurgia Biochemicals Ltd reported revenue of ₹0.0 Cr and a net loss of ₹0.1 Cr for the Jun 2026 quarter. Earnings per share were −₹0.01 (as of 19 October 2026). ### What is Citurgia Biochemicals's market cap? Citurgia Biochemicals Ltd's market capitalisation is ₹1,449 Cr at a share price of ₹102.45. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 19 October 2026). ### How is Citurgia Biochemicals performing? Citurgia Biochemicals Ltd's share price has been rising for 26 weeks. This describes what the data did, not a rating (as of 19 October 2026). ### Is Citurgia Biochemicals in an uptrend? Yes, the price has been rising for 26 weeks (stage 2 of 4), 26.0% above its 200-day average, and at its lowest point of the past 52 weeks. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 19 October 2026). ### Will Citurgia Biochemicals's share price go up? This page does not forecast Citurgia Biochemicals Ltd's share price. What it shows instead: the share price is ₹102.45, and it has been rising for 26 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 19 October 2026). ### Who owns Citurgia Biochemicals? Promoters own 99.4% of Citurgia Biochemicals Ltd, foreign institutions , domestic institutions, and the public 0.6% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 19 October 2026). ### What could break the Citurgia Biochemicals story? Biggest thing to watch: the price has already been rising for 26 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 19 October 2026). ### Is Citurgia Biochemicals a stock worth studying right now? What the numbers show: Citurgia Biochemicals Ltd's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 19 October 2026). This is research, not advice. We’re not SEBI-registered.